Treatment of Cutaneous Squamous Cell Carcinoma
For low-risk primary cutaneous squamous cell carcinoma, perform standard surgical excision with 4-6 mm margins to the mid-subcutaneous fat with histologic margin assessment; for high-risk tumors, Mohs micrographic surgery is the recommended treatment. 1
Risk Stratification Determines Treatment Approach
The treatment algorithm hinges entirely on whether the tumor is classified as low-risk or high-risk. High-risk features include: depth >4mm, perineural invasion, lymphovascular invasion, poor differentiation, aggressive histologic subtypes, invasion of fascia/muscle/bone, location on high-risk anatomic sites, recurrent tumors, and immunosuppression 1.
Surgical Treatment by Risk Category
Low-Risk Primary cSCC
- Standard excision with 4-6 mm clinical margins extending to mid-subcutaneous adipose tissue with complete histologic margin assessment 1
- Curettage and electrodesiccation may be considered only in non-terminal hair-bearing locations 1
- Average local recurrence rate with standard excision is 5.4% 1
High-Risk Primary cSCC
- Mohs micrographic surgery (MMS) is the recommended treatment 1
- MMS provides complete margin assessment and tissue preservation, critical for high-risk tumors
- Standard excision may be considered for select high-risk tumors, but strong caution is advised when treating high-risk tumors without complete margin assessment 1
- For high-risk lesions >2 cm or higher histologic grade, at least 6-mm margins are required to achieve 95% clearance rates with standard excision 1
Critical Pitfall: Incomplete excisions occur in 8.8% of cases with standard excision 1. Achieving clear surgical margins is the single most important treatment consideration for cSCCs amenable to surgery 2.
Non-Surgical Options (When Surgery Not Feasible)
Radiation Therapy
- Can be considered for low-risk tumors when surgery is not feasible or preferred, but cure rates may be lower 1
- Options include superficial radiation therapy, brachytherapy, or external electron beam 1
- Smaller and thinner tumors are more responsive 1
Limited-Use Modalities
- Cryosurgery: Only for low-risk lesions when more effective therapies are contraindicated or impractical 1
- Topical therapies (imiquimod, 5-FU) and photodynamic therapy are NOT recommended for invasive cSCC based on available data 1
- Insufficient evidence exists for laser therapies or electronic surface brachytherapy 1
Advanced Disease Management
Regional Lymph Node Metastases
- Surgical resection (lymph node dissection) with or without adjuvant radiation therapy and possible systemic therapy 1
- Combination chemoradiation for inoperable disease 1
Locally Advanced or Metastatic Disease (Not Amenable to Surgery/Radiation)
- Anti-PD-1 immunotherapy (cemiplimab or pembrolizumab) is first-line systemic treatment 2, 3
- Cemiplimab is the first FDA/EMA-approved systemic agent for advanced cSCC 2
- Second-line options: EGFR inhibitors (cetuximab) combined with chemotherapy or radiotherapy 1, 2
- Cisplatin as single agent or combined with 5-FU has shown some activity but limited data 1
Mandatory: Multidisciplinary consultation for all patients with locoregional or distant metastases, particularly immunosuppressed individuals 1, 2
Special Considerations for Immunosuppressed Patients
Solid organ transplant recipients (SOTRs) have 2-3 times higher metastatic risk 1. Consider:
- Dose reduction of immunosuppressive agents when appropriate 1
- Minimize calcineurin inhibitors (cyclosporine, tacrolimus) and antimetabolites (azathioprine) 1
- Consider switching to mTOR inhibitors (sirolimus), though recent data show mixed results 1
- Multidisciplinary management is strongly encouraged 1
Adjuvant Radiation Therapy
For primary cSCC with perineural invasion or high risk for regional/distant metastasis, adjuvant radiation to the local tumor site may be considered after surgical treatment, though high-level evidence is lacking 1. Current evidence has not shown significant benefit for adjuvant radiotherapy in patients with high-risk localized cSCC with clear surgical margins and at least one high-risk factor 2.
Palliative Care
Patients with advanced disease should be provided with or referred for best supportive and palliative care to optimize symptom management and maximize quality of life 1.